On the stock market since 1980, it operates in the world of health and science. It has 1,376 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 9% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
An investor who bought at the very peak is down 77% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $7.2M in the vault; even if every debt were paid off, $6.6M would remain.
It pays out $0.10 per share each year — regular cash for whoever holds the stock.
A loss of $1.5M against $32.4M in annual sales. And on top of that, sales fell from the year before.
On our five-subject report card, SSY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SSY is a small company that closed last year at a loss. The road back to profit runs through spending discipline.